Andrew Hirsch C4 Therapeutics, Inc. (CCCC) insider trading activity

Andrew Hirsch is President & CEO of C4 Therapeutics, Inc.. Currently has a direct ownership of 423,145 shares of CCCC, which is worth approximately $1.15 Million. The most recent transaction as insider was on Feb 15, 2025, when has been sold 9,370 shares (Common Stock) at a price of $3.18 per share, resulting in proceeds of $29,796. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 423K

90.72% 3M change

100.79% 12M change

Total Value Held $1.15 Million

Andrew Hirsch Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 15 2025	SELL Payment of exercise price or tax liability	$29,796 $3.18 p/Share	9,370 Reduced 2.17%	423,145 Common Stock
Feb 14 2025	SELL Payment of exercise price or tax liability	$40,853 $3.18 p/Share	12,847 Reduced 2.88%	432,515 Common Stock
Feb 14 2025	BUY Grant, award, or other acquisition	-	223,500 Added 33.41%	445,362 Common Stock
Nov 07 2024	SELL Payment of exercise price or tax liability	$33,522 $6.04 p/Share	5,550 Reduced 2.44%	221,862 Common Stock
Nov 07 2024	BUY Exercise of conversion of derivative security	-	12,500 Added 5.21%	227,412 Common Stock
Sep 16 2024	SELL Payment of exercise price or tax liability	$21,172 $6.36 p/Share	3,329 Reduced 1.53%	214,912 Common Stock
Sep 16 2024	BUY Exercise of conversion of derivative security	-	7,500 Added 3.32%	218,241 Common Stock
Feb 15 2024	SELL Payment of exercise price or tax liability	$51,824 $7.9 p/Share	6,560 Reduced 3.02%	210,741 Common Stock
Feb 14 2024	BUY Grant, award, or other acquisition	-	103,400 Added 32.24%	217,301 Common Stock
Aug 30 2023	SELL Payment of exercise price or tax liability	$6,460 $2.93 p/Share	2,205 Reduced 1.9%	113,901 Common Stock
Aug 30 2023	BUY Exercise of conversion of derivative security	-	7,500 Added 6.07%	116,106 Common Stock
Feb 15 2023	BUY Grant, award, or other acquisition	-	81,600 Added 42.9%	108,606 Common Stock
Jan 30 2023	SELL Payment of exercise price or tax liability	$33,601 $7.78 p/Share	4,319 Reduced 13.79%	27,006 Common Stock
Jan 30 2023	BUY Exercise of conversion of derivative security	-	12,500 Added 28.52%	31,325 Common Stock
May 25 2022	BUY Exercise of conversion of derivative security	-	12,500 Added 35.71%	22,500 Common Stock
Apr 12 2022	BUY Open market or private purchase	$84,000 $8.4 p/Share	10,000 Added 50.0%	10,000 Common Stock

Also insider at

EDIT

Editas Medicine, Inc. Healthcare

Director

Andrew Hirsch

President & CEO

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CCCC shares.

Notify only if

Value

Insider Trading

Get notified when an C4 Therapeutics, Inc. insider buys or sells CCCC shares.

Notify only if

Operation

Value

Type

News

Receive news related to C4 Therapeutics, Inc.

Track Activities on CCCC

Account